Peptide Receptor Radionuclide Therapy
A targeted radiotherapy using radiolabeled somatostatin analogs to treat neuroendocrine tumors expressing somatostatin receptors.
Full Definition
Peptide Receptor Radionuclide Therapy (PRRT) is a form of targeted molecular radiotherapy that uses radiolabeled somatostatin analogs to deliver radiation directly to neuroendocrine tumor cells expressing somatostatin receptors. The therapy typically employs lutetium-177 or yttrium-90 labeled peptides that bind to somatostatin receptors on tumor cells, delivering localized radiation while sparing normal tissues. PRRT has shown significant efficacy in controlling symptoms and extending progression-free survival in patients with advanced, well-differentiated neuroendocrine tumors. Treatment typically involves multiple cycles administered over several months with careful monitoring for potential side effects including bone marrow suppression and renal toxicity.
Usage
Usage note: Can be abbreviated as PRRT; spell out on first use in documents.
In Context
- "The patient was referred for peptide receptor radionuclide therapy following progression on somatostatin analog treatment." — Referral letter
- "Peptide receptor radionuclide therapy with lutetium-177 DOTATATE resulted in significant tumor shrinkage and symptom improvement." — Treatment response assessment